Caroline B Kurtz Selected Research

Guanylate Cyclase (Guanylyl Cyclase)

10/2018	Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.
1/2018	Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
1/2014	Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain.
12/2013	Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
9/2013	Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.
1/2013	Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
12/2010	Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
12/2010	Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
3/2010	Efficacy of linaclotide for patients with chronic constipation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Caroline B Kurtz Research Topics

Disease

16	Constipation 01/2018 - 09/2007
10	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 04/2014 - 09/2007
8	Diarrhea 01/2018 - 07/2004
5	Abdominal Pain (Pain, Abdominal) 10/2018 - 12/2010
4	Hypersensitivity (Allergy) 10/2018 - 09/2007
4	Pain (Aches) 04/2014 - 03/2010
2	Hyperammonemia 01/2021 - 01/2019
2	Inflammation (Inflammations) 01/2021 - 09/2013
2	Phenylketonurias (Phenylketonuria) 01/2021 - 10/2018
1	Hyperoxaluria (Oxaluria) 01/2022
1	Kidney Calculi (Kidney Stone) 01/2022
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	Renal Insufficiency (Renal Failure) 01/2022
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021
1	Rare Diseases (Rare Disease) 01/2021
1	Hepatic Encephalopathy 01/2019
1	Inborn Urea Cycle Disorders 01/2019
1	Colitis 10/2018
1	Inborn Genetic Diseases (Disease, Hereditary) 10/2018
1	Visceral Pain 01/2014
1	Carcinoma (Carcinomatosis) 12/2010
1	Infections 07/2004

Drug/Important Bio-Agent (IBA)

17	linaclotideIBA 10/2018 - 09/2007
9	Guanylate Cyclase (Guanylyl Cyclase)IBA 10/2018 - 03/2010
5	Peptides (Polypeptides)IBA 01/2013 - 03/2010
3	AcidsIBA 12/2010 - 05/2010
2	Phenylalanine (L-Phenylalanine)FDA Link 01/2021 - 10/2018
2	AmmoniaIBA 01/2021 - 01/2019
1	OxalatesIBA 01/2022
1	EndotoxinsIBA 01/2021
1	Hydroxyproline (4 Hydroxyproline)IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Thioacetamide (Thioacetamid)IBA 01/2019
1	Ornithine Carbamoyltransferase (Ornithine Transcarbamylase)IBA 01/2019
1	Analgesics (Analgesic Drugs)IBA 01/2014
1	GuanosineIBA 12/2013
1	guanylinIBA 09/2013
1	uroguanylinIBA 09/2013
1	Sulfonic AcidsIBA 09/2013
1	Hormones (Hormone)IBA 09/2013
1	Guanylyl Cyclase C AgonistsIBA 12/2010
1	SaltsIBA 07/2004
1	PolymersIBA 07/2004
1	Pharmaceutical PreparationsIBA 07/2004
1	styrenesulfonic acid polymerIBA 07/2004
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2004
1	Styrene (Styrol)IBA 07/2004
1	SodiumIBA 07/2004

Therapy/Procedure

1	Therapeutics 03/2010